| First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn’s disease: an open-label multicentre randomised … MME Jongsma, MA Aardoom, MA Cozijnsen, M Van Pieterson, T De Meij, ... Gut 71 (1), 34-42, 2022 | 94 | 2022 |
| Infliximab in young paediatric IBD patients: it is all about the dosing MME Jongsma, DA Winter, HQ Huynh, L Norsa, S Hussey, KL Kolho, ... European journal of pediatrics 179, 1935-1944, 2020 | 67 | 2020 |
| Development and validation of the mucosal inflammation noninvasive index for pediatric Crohn’s disease MA Cozijnsen, AB Shoham, B Kang, BH Choe, YH Choe, MME Jongsma, ... Clinical Gastroenterology and Hepatology 18 (1), 133-140. e1, 2020 | 56 | 2020 |
| Vedolizumab trough levels in children with anti-tumor necrosis factor refractory inflammatory bowel disease MA Aardoom, MME Jongsma, A de Vries, J Wolthoorn, L de Ridder, ... Journal of Pediatric Gastroenterology and Nutrition 71 (4), 501-507, 2020 | 12 | 2020 |
| Serum Immune Profiling in Paediatric Crohn’s Disease Demonstrates Stronger Immune Modulation With First-Line Infliximab Than Conventional Therapy and Pre-Treatment Profiles … MME Jongsma, LMM Costes, I Tindemans, MA Cozijnsen, ... Journal of Crohn's and Colitis 17 (8), 1262-1277, 2023 | 11 | 2023 |
| The use of biosimilars in paediatric inflammatory bowel disease MME Jongsma, A Vulto, L de Ridder Current Opinion in Pediatrics 29 (5), 560-565, 2017 | 6 | 2017 |
| OP38 Top-down infliximab superior to step-up in children with Moderate-to-Severe Crohn’s disease: A multicentre randomised controlled trial M Jongsma, M Aardoom, M Cozijnsen, M Van Pieterson, T De Meij, ... Journal of Crohn's and Colitis 14 (Supplement_1), S039-S039, 2020 | 5 | 2020 |
| Randomised clinical trial: first‐line infliximab biosimilar is cost‐effective compared to conventional treatment in paediatric Crohn's disease SA Vuijk, MME Jongsma, BM Hoeven, MA Cozijnsen, M van Pieterson, ... Alimentary Pharmacology & Therapeutics 59 (12), 1510-1520, 2024 | 2 | 2024 |
| Evaluation of exclusive enteral nutrition and corticosteroid induction treatment in new-onset moderate-to-severe luminal paediatric Crohn’s disease MME Jongsma, SA Vuijk, MA Cozijnsen, M Van Pieterson, OF Norbruis, ... European journal of pediatrics 181 (8), 3055-3065, 2022 | 2 | 2022 |
| DOP67 First-line infliximab is cost-effective compared to conventional treatment in paediatric Crohn’s Disease–Results from the TISKids study S Vuijk, M Jongsma, B Hoeven, M Cozijnsen, M van Pieterson, T de Meij, ... Journal of Crohn's and Colitis 16 (Supplement_1), i111-i112, 2022 | 2 | 2022 |
| Infliximab level between venous and capillary blood using novel device strongly correlate in paediatric inflammatory bowel disease patients M Zijlstra, MME Jongsma, A de Vries, T Schaap, K Bloem, L de Ridder Journal of Pediatric Gastroenterology and Nutrition 72 (1), 56-60, 2021 | 2 | 2021 |
| Infliximab level between venous and capillary blood using novel device strongly correlate in paediatric IBD patients M Zijlstra, MME Jongsma, A de Vries, T Schaap, K Bloem, L de Ridder Journal of Pediatric Gastroenterology and Nutrition, 2020 | 2 | 2020 |
| 947 TOP-DOWN INFLIXIMAB SUPERIOR TO STEP-UP IN CHILDREN WITH MODERATE-TO-SEVERE CROHN'S DISEASE-A MULTICENTER RANDOMIZED TRIAL M Jongsma, M Aardoom, M Cozijnsen, M van Pieterson, T de Meij, ... Gastroenterology 158 (6), 193, 2020 | 2 | 2020 |
| Infliximab Monotherapy vs Combination Therapy for Pediatric Crohn’s Disease Exhibit Similar Pharmacokinetics RJ Colman, SA Vuijk, RAA Mathôt, J Van Limbergen, MME Jongsma, ... Inflammatory Bowel Diseases, izad307, 2024 | 1 | 2024 |
| P440 Comparison of infliximab serum levels between venous and capillary blood in paediatric IBD patients using novel blood sampling technology M Zijlstra, M Jongsma, A de Vries, T Schaap, K Bloem, L de Ridder Journal of Crohn's and Colitis 13 (Supplement_1), S330-S331, 2019 | 1 | 2019 |
| Combined plasma protein and Tmem profiling discern IBD-patient-immunotypes related to intestinal disease and treatment outcomes: Short title: Defining immunotypes in CD and UC M Heredia, M Charrout, RCW Klomberg, MA Aardoom, MME Jongsma, ... Mucosal Immunology, 2024 | | 2024 |
| P448 Long term effectiveness of first-line infliximab treatment compared to conventional treatment in paediatric moderate-to-severe Crohn’s disease–an update from the TISKids study S Vuijk, M Jongsma, M Cozijnsen, M van Pieterson, T de Meij, O Norbruis, ... Journal of Crohn's and Colitis 17 (Supplement_1), i579-i580, 2023 | | 2023 |
| P100 Serum inflammatory protein profiling to corroborate selection of therapy naïve moderate-to-severe pediatric Crohn’s disease patients eligible for first-line infliximab … MME Jongsma, LMM Costes, I Tindemans, MA Cozijnsen, ... Journal of Crohn's and Colitis 16 (Supplement_1), i197-i198, 2022 | | 2022 |
| P021 Circulating inflammatory protein and cellular profiles at time of diagnosis classify inflammatory bowel disease patients according to their underlying immune response and … M Heredia, M Charrout, R Klomberg, M Aardoom, M Jongsma, P Kemos, ... Journal of Crohn's and Colitis 15 (Supplement_1), S139-S139, 2021 | | 2021 |
| P019 Differential effects of first-line IFX and conventional treatment on inflammatory serum proteins of paediatric moderate-to-severe Crohn’s disease patients M Jongsma, LMM Costes, I Tindemans, MA Cozijnsen, RHC Raatgeep, ... Journal of Crohn's and Colitis 15 (Supplement_1), S137-S138, 2021 | | 2021 |
